Biotech
Avalon Pharmaceuticals(AVRX) says it's initiating a drug discovery program for a new type of cancer treatment.
The research effort will target a specific molecule known as survivin, which is responsible for cancer growth and death in breast, lung, prostate, pancreatic and colon cancers. "Avalon Pharmaceuticals is especially well-suited to undertake a discovery program for this intractable cancer pathway," said Dr. Kenneth Carter, Avalon's president and CEO. "Our AvalonRx technology identifies potential therapeutics based upon their ability to modulate pathways or targets within living cells. Avalon's pipeline also includes drugs being developed in collaboration with MedImmune(MEDI), Novartis(NVS), ChemDiv and Medarex(MEDX). Avalon's shares were up 11.1% to $3.30.TheStreet Premium Services
Jim Cramer's Action Alerts PLUS:
Trade right alongside a Wall Street pro — enjoy access to his Charitable Trust portfolio and be sent trade alerts BEFORE he makes a move. Learn More
OptionsProfits:
Get 50+ trade ideas a week from the industry's top options experts. Plus — exclusive commentary on market trends and essential trading tools. Learn More
Real Money:
Our team of professional Wall Street Pros — including Jim Cramer, Doug Kass, and Nicholas Vardy — delivers intelligent analysis, timely trade ideas, and colorful commentary. Learn More
Stocks Under $10:
Break into the market with small- and mid-cap stocks... all $10 or less! David Peltier tells you exactly which low-priced stocks he's buying and selling. Learn MoreTo begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
blog comments powered by Disqus
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,393.45 | 1,310.33 | 2,827.34 | 15.81 |
Oil *
101.78
|
|
DOWN
26.41 |
DOWN
2.99 |
DOWN
10.02 |
DOWN
0.44 |
10 Yr
1.58%
SPDR Gold
151.62
|
|
-0.21%
|
-0.23%
|
-0.35%
|
-2.71%
|
Data delayed 20 minutes |
Connect with TheStreet